Original Article:
Integrative metabolic profile of myelodysplastic syndrome based on UHPLC–MS
Yunxia Yuan, et al.
Biomedical Chromatography, 2021, 35(9), e5136.
10.1002/bmc.5136
Myelodysplastic syndrome (MDS) is a neoplastic disease originating from hematopoietic stem cells. This work assessed changes in endogenous metabolites and investigated metabolic pathways associated with MDS by applying UHPLC-MS (Ultra High Performance Liquid Chromatography-MS) metabolomics approach. An untargeted metabolomics approach based on UHPLC-MS combined with multivariate data analysis was established to investigate potential biomarkers in the plasma of MDS patients. This study is the first to combine plasma metabolomics with HSCT to investigate the pathogenesis and therapeutic targets of MDS.
In this study, 29 biomarkers were identified to distinguish MDS patients, HSCT patients and healthy controls, including 2-Hydroxysebacic Acid. The metabolic pathway of 2-hydroxysebacic acid is fatty acid biosynthesis. The results of metabolic pathway analysis showed that the plasma concentration of 2-hydroxysebacic acid was higher than that of the normal group, suggesting that fatty acid metabolism disorder in MDS patients.
Chemicals Related in the Paper:
| Catalog Number | Product Name | Structure | CAS Number | Price |
|---|---|---|---|---|
| ACM103963719 | 2-Hydroxysebacic Acid |  |
103963-71-9 | Price |
